Where to buy Fam-trastuzumab deruxtecan-nxki

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate for the treatment of HER2-positive breast cancer, HER2-low breast cancer, HER2-mutant non-small cell lung cancer, and HER2-positive gastric or gastroesophageal junction adenocarcinoma. The active substance in trastuzumab deruxtecan consists of two active ingredients, which are linked to each other.

Trastuzumab is a monoclonal antibody (a protein) designed to attach to HER2. By linking to HER2, trastuzumab activates cells of the immune system, which then kills cancer cells. Trastuzumab also prevents HER2 from stimulating the growth of cancer cells. HER2 is produced at high levels in about one-fifth of stomach cancers and one-quarter of breast cancers, and at lower levels in about half of the remaining breast cancers. Deruxtecan is a toxic substance that kills cells when they try to divide and grow. Once the trastuzumab component attaches to HER2 and enters the cancer cell, it becomes active. Deruxtecan blocks an enzyme called topoisomerase I, which is involved in copying the cell's DNA needed to make new cells. By blocking topoisomerase I, cancer cells are prevented from proliferating and eventually die.

Trastuzumab is a new type of injectable anti-cancer drug. The original drug has been launched in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase method is difficult. The Hong Kong version of TrastuzumabSpecifications100mg may cost more than 10,000 yuan per box, and the Hong Kong original versionTrastuzumabOriginal drug specificationsThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to exchange rate effects). The drug ingredients of the two are basically the same. There is currently no generic drug of Trastuzumab produced and launched. For more specific prices and drug information, please consult the medical consultant of the drug.